Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psychedelic-based therapeutics for mental health conditions like major depressive disorder and generalized anxiety disorder.

Cybin Inc. CEO Doug Drysdale will be speaking at the H.C. Wainwright Neuro Perspectives Conference and the Psychedelic Science 2025 Conference, highlighting the company's focus on developing psychedelic-based therapeutics for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. has filed an application for a preservative-free ketamine formulation to address the shortage of ketamine in the U.S., and Silo Pharma Inc. has received a patent related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders, strengthening its position in the field of psychedelic therapeutics.

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has acquired Kadima Neuropsychiatry Institute to establish a network of interventional psychiatry clinics. The subsidiary, HOPE Therapeutics, aims to open up to 30 clinics by 2025, with a projected $100 million run rate. NRx has also filed an ANDA for its preservative-free IV ketamine formulation, NRX-100, targeting the U.S. ketamine market and seeking to broaden its label for treating suicidal depression.

Rythmia Life Advancement Center's new affiliate program targets wellness influencers, healers, and marketers to promote its life-changing experiences in Costa Rica. Offering competitive commissions and second-tier referral earnings, partners can share in Rythmia's mission of healing and transformation while earning income. Visit Rythmia's website for more details on this unique opportunity.

Cybin Inc. has obtained a U.S. patent for its CYB004 anxiety treatment candidate, extending exclusivity through 2040. CEO Doug Drysdale emphasized the potential of CYB004 to provide rapid-acting, short-duration treatment with a patient-friendly delivery system. The compound is in Phase 2 trials, projected to conclude by mid-2025, solidifying Cybin's position as a frontrunner in innovative mental health therapies.

Stonegate Capital Partners provided an update on Incannex Healthcare Inc., reporting reduced expenses and strengthened financial position. Lophora initiated a Phase 1 trial for LPH-5 targeting CNS disorders, aiming to provide therapeutic benefits without hallucinogenic effects. NRx Pharmaceuticals announced a $10.3 million financing to expand its HOPE Clinic Network and advance FDA drug approval for neuroplastic therapies.

Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.

Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.

Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.

Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health conditions.